Results 71 to 80 of about 13,452 (217)
The Turkish Journal of Pediatrics, 2019 Hyperphosphatemic familial tumoral calcinosis is a rare autosomal recessive disorder that is characterized by persistent hyperphosphatemia and extra-articular calcifications.
Jumana Albaramki +5 more
doaj +1 more source
Klinicist, 2018 The aim of study is to reflect the possibilities and effectiveness of teriparatide for the treatment of postoperative hypoparathyroidism associated with severe systemic osteoporosis, based on the data of the clinical case.Materials and methods. Patient N.
G. A. Batrak +2 more
doaj +1 more source
Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients
Journal of the Formosan Medical Association, 2010 Sevelamer hydrochloride is a recently developed phosphate binder, which is a quaternary amine anion exchanger without calcium or aluminum. Sevelamer is effective in controlling hyperphosphatemia without increasing the calcium load in chronic hemodialysis
Yu-Feng Lin +13 more
doaj +1 more source
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
Kidney International Reports, 2018 Serum phosphate levels are insufficiently controlled in many patients with end-stage renal disease (ESRD), and novel therapeutic strategies are needed. Blocking intestinal phosphate absorption mediated by sodium-dependent phosphate co-transporter type 2b
Tobias E. Larsson +6 more
doaj +1 more source
Reply to correspondence letter: enema-induced severe hyperphosphatemia in children [PDF]
, 2009 Ariane Biebl
openalex +1 more source
Urinary Fractional Excretion of Phosphorus in Dogs with Spontaneous Chronic Kidney Disease
Veterinary Sciences, 2017 The increase of urinary fractional excretion of phosphorus (uFEP) may indicate phosphorus retention before the onset of hyperphosphatemia in the early stages of chronic kidney disease (CKD).
Cínthia Ribas Martorelli +6 more
doaj +1 more source
SP404THE EFFECTS OF A SERIOUS GAME ON KNOWLEDGE OF CKD, HYPERPHOSPHATEMIA, AND PHOSPHATE BINDERS IN CKD PATIENTS STAGE 4/5: A PROSPECTIVE MULTINATIONAL STUDY [PDF]
, 2015 Pamela M. Kato, Peter C. Hill
openalex +1 more source
New Developments in Hyperphosphatemia Management [PDF]
Journal of the American Society of Nephrology, 2003 Patients with chronic renal failure have many associated medical problems, including a high propensity for cardiovascular disease (CVD). CVD and stroke are the leading causes of mortality in patients with ESRD (chronic kidney disease stage 5), with a 10- to 20-fold greater risk than in the general population (1,2).
openaire +2 more sources
Control of hyperphosphatemia beyond phosphate [PDF]
Kidney International, 2007 Hyperphosphatemia is a prevalent condition in the dialysis population and is associated with bad outcome. Block et al. present data from a post hoc analysis indicating that sevelamer, a noncalcium-containing phosphate binder, may confer a survival benefit in incident hyperphosphatemic hemodialysis patients.
openaire +2 more sources
Safety and Phosphate‐Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers
Clinical and Translational ScienceDespite the widespread use of currently available serum phosphate management options, elevated serum phosphate is common in patients with end‐stage kidney disease on dialysis.
Pablo E. Pergola +7 more
doaj +1 more source